Forecasts Significant Growth in Erectile Dysfunction Market, Expects CAGR of 6.2% and surpasses US$ 10.14 billion by 2030
Erectile Dysfunction Market, By Therapy Type (Drug Therapy and Device Therapy), and By Region (North America, Asia Pacific, Europe, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030
Sample link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/141
Key Highlights:
In 2019, Boston Scientific (NYSE:BSX) recently launched what it describes as a durable, natural-feeling implant to treat erectile dysfunction.
In 2021, -Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG).
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/141
Key Highlights:
In 2019, Boston Scientific (NYSE:BSX) recently launched what it describes as a durable, natural-feeling implant to treat erectile dysfunction.
In 2021, -Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG).
- Contact Email
- [email protected]
- Issued By
- nikita gawade
- Phone
- 91 7775049802
- Business Address
- BadilloStreet
- Country
- United States
- Categories
- Health
- Last Updated
- July 19, 2023